4 Results Today, 13th May 2026 Live Updates: Find all the latest Q4 results 2026 updates of Abhijit Trading Company, Andhra Cements, Adf Foods, Aeroflex Enterprises, Balaji Amines, The Bombay Burmah Trading Corporation, Bharti Airtel, Bharti Hexacom, Black Rose Industries, Bombay Potteries & Tiles, CARE Ratings, Chemfab Alkalis, Cipla, CL Educate, Concord Control Systems, Crompton Greaves Consumer Electricals, CyberTech Systems and Software, DCM Shriram, DIC India, Digispice Technologies, DLF, eClerx Services, Ester Industries, Euphoria Infotech (India), Expleo Solutions, Flora Corporation, Gallard Steel, GK Energy, GlaxoSmithKline Pharmaceuticals, Gujarat Petrosynthese, Hindustan Petroleum Corporation, Hypersoft Technologies, IEC Education, Inventurus Knowledge Solutions, Interarch Building Solutions, Jayshree Chemicals, Jet Freight Logistics, Jetmall Spices and Masala, JSL Industries, JSW Dulux, Jupiter Infomedia, Kaynes Technology India, Kirloskar Brothers, Laxmi India Finance, LIC Housing Finance, Loyal Equipments, Man Infraconstruction, Mangal Electrical Industries, Metropolis Healthcare, Modi Naturals, Nitco, NLC India, Neopolitan Pizza And Foods, Oil India, OM Infra, Onesource Specialty Pharma, Panth Infinity, Paras Defense and Space Technologies, Perfectpac, Permanent Magnets, Pune E – Stock Broking, Power Finance Corporation, Photoquip India, Progrex Ventures, Pyramid Technoplast, Quality Power Electrical Equipments, Redington, Sodhani Academy of Fintech Enablers, Sagar Systech, Sagar Cements, Sangam Finserv, SecMark Consultancy, Seshachal Technologies, Sharda Cropchem, Sicagen India, Signatureglobal (India), SKF India, Smartlink Holdings, Smruthi Organics, Shree Ram Twistex, Stallion India Fluorochemicals, Starteck Finance, Suditi Industries, Sunshield Chemicals, Suven Life Sciences, SW Investments, Texmaco Infrastructure & Holdings, Tourism Finance Corporation of India, Transwarranty Finance, The Investment Trust Of India, Tube Investments of India, Tata Motors, TVS Holdings, TVS Motor Company, Veefin Solutions, Vega Jewellers, Yash Highvoltage, Zaggle Prepaid Ocean Services, Ardi Investments & Trading Company, and ZF Commercial Vehicle Control Systems India.
- May 13, 2026 10:02
Reviews
Q4 results update: Analysts’ take on Dr Reddy’s
Morgan Stanley On Dr Reddy’s
Maintain Equal-weight; Target Price: ₹1,215 (vs ₹1,259 earlier)
Q4 adjusted revenue and EBITDA miss estimates by 2% and 13% respectively
Semaglutide ramp-up slightly delayed awaiting Brazil approval
Management expects 6-7 mn pen sales in CY26 and 40mn+ capacity in FY28
US business stabilizing post gRevlimid with double-digit FY27 growth guidance
Brokerage cuts FY27/FY28 EPS estimates by 3% and 3.5% respectively
Execution risks and weak US generics backdrop keep margin outlook subdued
Morgan Stanley values DRL at 19x March 2028E P/E
Goldman Sachs On Dr Reddy’s
Maintain Sell; Target Price: ₹1,050 (vs ₹1,075 earlier)
Q4 revenue and EBITDA margin miss estimates amid lower lenalidomide sales
One-time shelf stock adjustment impacts profitability
Brokerage revises FY27-29 EPS estimates by -9% to +3%
Goldman Sachs concerned about overall Olympic opportunity in Canada
Near-to-medium-term pipeline for higher value products remains thin
Key base business products facing intense price erosion
Citi On Dr Reddy
Recommendation: Sell; Target: ₹1,070
Reality check on numbers as gRevlimid tailwinds fade
US sales have fallen at pre-grevlimid levels, indicating erosion in the base-line products.
Core profitability and US revenues remain under pressure
Strong growth in non-US markets appears increasingly cost-funded and dilutive to margins
Nomura on DR Reddys
Buy, TP Rs 1600
4Q: Adjusted for one-off items, estimate sales were 1% ahead of estimate & EBITDA 3% below estimate
Co expects double-digit revenue growth to sustain across all markets excluding NAG.
Even in NAG, excluding contribution from gRevlimid in FY26 & likely contribution from Semaglutide in Canada in FY27F, company expects double-digit Growth
Company expects gross margin at 50-55% going ahead (vs 48% adjusted gross margin in 4QFY26) and EBITDA margin (including other income) at 20% exSemaglutide
Jefferies on DR Reddys
UP, TP Rs 1040
Mar-26Q was weak & missed estimates materially, even after adjusting for multiple one-offs.
Margins declined on weak US performance and high SG&A even though India, Russia and Europe delivered growth.
Mgt guided for double-digit YoY revenue growth in FY27 ex gRevlimid, in line with expectations.
Slower uptake of semaglutide in Canada and delay in launch of Abatacept pose downside risks to our est.
- May 13, 2026 09:59
Quarterly results
Q4 results live: Abbott India Announces Record ₹656 Dividend
MNC pharma giant Abbott India has declared a massive ₹656 per share dividend — one of the highest payouts in the Indian pharma space.
Q4 Revenue rises 6.5% YoY to ₹1,709 Cr
EBITDA jumps 12.2% YoY to ₹481 Cr
EBITDA margin improves by 140 bps
Net Profit rises to nearly ₹395 Cr
Around 71,000 retail shareholders set to benefit
Despite a challenging market environment, Abbott India continues to demonstrate the strength of MNC pharma business models through consistent cash generation, strong margins and shareholder-friendly capital allocation.
- May 13, 2026 09:58
Quarterly results
Q4 results live: AVADH SUGAR & ENERGY Q4 RESULTS
Net Profit: ₹55.61 Cr, down 22.4% YoY, up 233.1% QoQ
Revenue: ₹670.61 Cr, down 1.2% YoY, up 5.1% QoQ
EBITDA: ₹119.61 Cr, down 19.9% YoY, up 116.0% QoQ
Margins: 17.8% vs 22.0% YoY, 17.8% vs 8.7% QoQ
- May 13, 2026 09:56
Quarterly results
Q4 results live: KAMAT HOTELS Q4 RESULTS
Net Profit: ₹16.39 Cr, up 49.2% YoY, down 5.3% QoQ
Revenue: ₹110.12 Cr, up 19.2% YoY, down 6.5% QoQ
EBITDA: ₹31.91 Cr, up 28.5% YoY, down 18.2% QoQ
Margins: 29.0% vs 26.9% YoY, 29.0% vs 33.1% QoQ
- May 13, 2026 09:55
Quarterly results
Q4 results live: SESHASAYEE PAPER Q4 RESULTS
Net Profit: ₹26.05 Cr, down 4.3% YoY, up 39.8% QoQ
Revenue: ₹591.84 Cr, up 17.8% YoY, up 53.0% QoQ
EBITDA: ₹23.59 Cr, down 6.5% YoY, down 4.5% QoQ
Margins: 4.0% vs 5.0% YoY, 4.0% vs 6.4% QoQ
- May 13, 2026 09:53
Quarterly results
Q4 results live: BOROSIL RENEWABLES Q4 RESULTS
NET PROFIT TURNAROUND TO ₹169.14 CR VS LOSS OF ₹20.10 CR (YOY) | UP 69.0% (QOQ) (Tax credit boosted PAT)
REVENUE UP 17.8% AT ₹439.92 CR (YOY) | UP 12.7% (QOQ)
EBITDA UP 782.5% AT ₹136.38 CR (YOY) | UP 10.8% (QOQ)
MARGINS 31.0% VS 4.1% (YOY) | 31.0% VS 31.5% (QOQ)
Published on May 13, 2026